Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related
Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus® platform
Short-Sellers Betting Against These Biotechs
Related ACAD
Viking Global Liked AIG, Google, Actavis, Illumina And Cheniere Energy Last Quarter
Benzinga's Top Initiations

Analysts at Deutsche Bank initiated coverage on shares of Sarepta Therapeutics (NASDAQ: SRPT) with a “buy” rating. The target price range for Sarepta Therapeutics is set to $45. Sarepta Therapeutics' shares closed at $33.03 yesterday.

Jefferies initiated coverage on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) with a “buy” rating. The target price for ACADIA Pharmaceuticals is set to $13. ACADIA Pharmaceuticals' stock closed at $6.18 yesterday.

Topeka Capital initiated coverage on shares of Schnitzer Steel Industries (NASDAQ: SCHN) with a “hold” rating. The target price for Schnitzer Steel Industries is set to $27. Schnitzer Steel Industries' shares closed at $28.60 yesterday.

Analysts at Bank of America initiated coverage on shares of Pluristem Therapeutics (NASDAQ: PSTI) with a “hold” rating. The target price for Pluristem Therapeutics is set to $3.50. Pluristem Therapeutics' shares closed at $3.17 yesterday.

Latest Ratings for SRPT

DateFirmActionFromTo
May 2015Bank of AmericaDowngradesBuyNeutral
May 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
May 2015Canaccord GenuityUpgradesHoldBuy

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ACAD + PSTI)

Get Benzinga's Newsletters